Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.72 USD | -2.10% | -5.08% | -33.87% |
Mar. 28 | Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target | MT |
Mar. 13 | Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.87% | 4.11B | |
-0.86% | 41.35B | |
+42.10% | 40.38B | |
+3.46% | 39.05B | |
-12.11% | 26.67B | |
+2.73% | 24.07B | |
-23.60% | 18.36B | |
-2.56% | 11.68B | |
+21.88% | 11.6B | |
+8.29% | 11.15B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant : Narrows Loss in Fiscal Q4